All In Biotech

Drug Trial Radar · NCT05688280

Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS

Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With Advanced Solid Tumors. A Multicenter Phase 1b/2a Trial in Colorectal Cancer, Non-small Cell Lung Cancer, and Soft Tissue Sarcoma Patients

Last checked: Nov 20, 2026Latest source record: Jan 8, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

42

Actual

Start

Nov 29, 2022

Primary completion

Feb 2025

Study completion Feb 2025

Sponsor

Lead sponsor
Immunophotonics, Inc.Industry
Sponsor type
Industry
First posted
Jan 18, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to determine the safety and efficacy of IP-001 for intratumoral injection administration following thermal ablation of a solid tumor.

Conditions

  • Metastatic Solid Tumor
  • Colon Cancer
  • Nonsmall Cell Lung Cancer
  • Soft Tissue Sarcoma

Interventions

  • 1.0% IP-001 for InjectionDrug

    4 mL 1.0% IP-001 for Injection following RFA every 6 weeks for up to 4 treatments.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and TolerabilityTime frame: Up to 12 weeks

Locations

16 sites in 5 countries. Site status is shown where the registry gives one.

  • Miami Cardiac & Vascular Institute

    Coral Gables, Florida

  • University of Louisville Physicians, PSC

    Louisville, Kentucky

  • Stephenson Cancer Center

    Oklahoma City, Oklahoma

  • Institut Bergonie

    Bordeaux, France

  • Hospitalier Pitie-Salpetriere

    Paris, France

  • Hôpital Foch

    Suresnes, France

  • Institut Gustave Roussy

    Villejuif, France

  • Johann Wolfgang Goethe-Univresitat Frankfurt/Main

    Frankfurt, Germany

  • SLK-Kliniken Heilbronn GmbH

    Heilbronn, Germany

  • Munchen Klinik Bogenhausen

    Munich, Germany

  • IOSI Ospedale San Giovanni Bellinzona

    Bellinzona, Switzerland

  • Inselspital Universitatsspital, Bern

    Bern, Switzerland

  • Kantonsspital Graubunden

    Chur, Switzerland

  • Kantonsspital St. Gallen

    Sankt Gallen, Switzerland

  • University College London Hospitals

    London, United Kingdom

  • Churchill Hospital

    Oxford, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.